Top 10 Pharmaceutical Stocks with Highest Upside: DARA, CYTR, EPCT, STEM, ANX, HEB, PATH, NABI, CXM, OCLS (Jan 16, 2012)
"Strong Buy" Rated U.S.-Listed Chinese Stocks (February 6, 2012)
Below are the top 10 Pharmaceutical stocks with highest upside potential, based on the difference between current price and Wall Street analysts' average target price.
DARA Biosciences Inc (NASDAQ:DARA) has the 1st highest upside potential in this segment of the market. Its upside is 1130.8%. Its consensus target price is $16.00 based on the average of all estimates. CytRx Corporation (NASDAQ:CYTR) has the 2nd highest upside potential in this segment of the market. Its upside is 760.8%. Its consensus target price is $2.35 based on the average of all estimates. EpiCept Corporation (NASDAQ:EPCT) has the 3rd highest upside potential in this segment of the market. Its upside is 600.0%. Its consensus target price is $1.75 based on the average of all estimates. StemCells, Inc. (NASDAQ:STEM) has the 4th highest upside potential in this segment of the market. Its upside is 599.5%. Its consensus target price is $5.50 based on the average of all estimates. ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) has the 5th highest upside potential in this segment of the market. Its upside is 593.8%. Its consensus target price is $4.25 based on the average of all estimates.
Hemispherx BioPharma, Inc (AMEX:HEB) has the 6th highest upside potential in this segment of the market. Its upside is 555.0%. Its consensus target price is $1.50 based on the average of all estimates. NuPathe Inc (NASDAQ:PATH) has the 7th highest upside potential in this segment of the market. Its upside is 441.9%. Its consensus target price is $12.58 based on the average of all estimates. Nabi Biopharmaceuticals (NASDAQ:NABI) has the 8th highest upside potential in this segment of the market. Its upside is 430.7%. Its consensus target price is $9.50 based on the average of all estimates. Cardium Therapeutics Inc (AMEX:CXM) has the 9th highest upside potential in this segment of the market. Its upside is 322.1%. Its consensus target price is $1.50 based on the average of all estimates. Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) has the 10th highest upside potential in this segment of the market. Its upside is 320.4%. Its consensus target price is $4.75 based on the average of all estimates.
